New CMV vaccine candidate enters first human tests
⭐️ VACCINE ⭐️
Completed
This early-stage trial tests a new vaccine called SPYVLP01 designed to protect against cytomegalovirus (CMV), a common virus that can cause serious problems in newborns and people with weak immune systems. The study involves 120 healthy adults aged 18 to 50 and will check if the …
Phase: PHASE1 • Sponsor: SpyBiotech Limited • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:51 UTC